Ovarian Cancer Market Size, Share Report, Analysis, Trends, Growth 2032

Ovarian Cancer Market: Industry Prospective

The global Ovarian Cancer market size accrued earnings worth approximately USD 4.24 Billion in 2023 and is predicted to gain revenue of about USD 26.52 Billion by 2032, is set to record a CAGR of nearly 22.6% over the period from 2024 to 2032. The study encompasses a market attractiveness analysis, where type, cancer stage, diagnostic, treatment, and regional segmentations are benchmarked based on their market size, growth rate, and general attractiveness.

Request Free Sample

Ovarian Cancer Market Outlook

Ovaries are located on each side of the uterus and are a part of the female reproductive system. Ovaries produce ovum and female hormones progesterone and estrogen. These female hormones manage the menstrual cycle along with influencing the development of female body characteristics. In normal conditions, human cells undergo division and fusion that results in the formation of new cells. New cells take the place of old or damaged cells. However, this process is disturbed when cancer develops. In cancer, the old or damaged cells survive and new cells keep appearing. This abnormality could lead to the formation of a tumor, a mass of cells. Ovarian cancer is a disease which involves the abnormal or cancerous growth of the cells in the ovaries. There are four major types of ovarian cancer: Epithelial ovarian cancer, Borderline tumors, Germ cell ovarian cancer, and Sex-cord stromal cell cancer. The cancer types are determined based on the location of the ovarian cells where the cancerous growth starts. After starting from ovaries, ovarian cancer spreads to the pelvis and abdomen region. Ovarian cancer is virtually undetectable when it is in the ovaries.

Request Free Sample

According to World Cancer Research Fund International, ovarian cancer comes in at the eighteenth number on the list of most common cancer and on the seventh number in the list of common cancer in women. The highest occurrence of ovarian cancer is found in North America and Europe. As per the estimates are given by American Cancer Society for previous years, in the United States around 22,400 women are expected to receive ovarian cancer diagnosis and around 14,070 ovarian cancer deaths will occur. Ovarian cancer causes more deaths than any other female reproductive system cancers. Ovarian cancer is the fifth leading cause of death due to cancer in women. About 1 in 78 women are at the risk of getting ovarian cancer. Women in the age group of 50 to 60 years are at a higher risk of getting ovarian cancer.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the market on the global and regional basis. 

Ovarian Cancer Market: Report Scope

Ovarian Cancer Market Growth Analysis

The strongest risk factors that can cause ovarian cancer are acquired genetic changes, genetic mutations called BRCA1 or BRCA2, old age, obesity, not having a full-term pregnancy, using fertility treatment, hormone therapy post menopause, and PTEN tumor hamartoma syndrome.

Factors such as increasing geriatric population of women rise in ovarian cancer cases, availability of new drugs and therapies, increase in healthcare expenditure, and increased government funding are expected to boost the growth of ovarian cancer market. However, availability of generic drugs and patent expiration of branded drugs can act as a restraint in the growth of the ovarian cancer market. The lack of precise diagnostic techniques for ovarian cancer in the early stages can also have a negative impact on the global ovarian cancer market.

Ovarian Cancer Market Segmentation Analysis

On the basis of the type the ovarian cancer market has been divided into epithelial ovarian tumors, ovarian germ cell tumors, ovarian stromal tumors, and primary peritoneal carcinoma. On the basis of the cancer stage, the market is segmented into Stage I, Stage II, Stage III, and Stage IV. On the basis of diagnostics, the market divided into the physical examination, biopsy, blood tests, Human Chorionic Gonadotropin (HCG) test, ultrasound, MRI (Magnetic resonance imaging), PET (Positron emission tomography), and CT scans. On the basis of treatment, the market divided into chemotherapy, targeted therapy, radiation therapy, immunotherapy, hormonal therapy, and surgery. In the forecast period, the diagnostic segment will dominate the global market as ovarian cancer is most chemo sensitive cancer.

Ovarian Cancer Market Regional Analysis

North America will be the dominant region during the forecast period. Increasing prevalence of ovarian cancer in the region and availability of latest diagnostic methods are the factors that will boost the ovarian cancer market in this region. Europe will be the second-largest market. The Asia Pacific will grow at the fastest rate over the forecast period. Increasing healthcare expenditure and growing attention towards ovarian cancer diagnosis are the driving factors for the growth of the ovarian cancer market in this region. Latin America market is projected to grow at a moderate rate during the forecast period. The Middle East and Africa are expected to experience noticeable growth in the years to come.

The report also includes detailed profiles of end players such as

• Astra Zeneca Plc
• Bristol Myers Squibb Company
• Genentech Inc.
• Eli Lilly and Company
• Novogen, Inc.
• GlaxoSmithKline Plc
• Janssen Pharmaceuticals, Inc.
• Aetera Zenteris Inc.
• Boehringer Ingelheim GmbH
• F. Hoffman-La Roche Ltd., and others.

This report segments the global ovarian cancer market as follows:

By Type

• Epithelial Ovarian Tumors 
• Ovarian Germ Cell Tumors
• Ovarian Stromal Tumors 
• Primary Peritoneal Carcinoma

By Cancer Stage

• Stage I
• Stage II
• Stage III
• Stage IV 

By Diagnostic

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Hormonal Therapy, and Surgery

By Treatment

• Chemotherapy
• Targeted Therapy
• Radiation Therapy
• Immunotherapy
• Hormonal Therapy
• Surgery

By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa